Affinity Asset Advisors LLC Takes $1.25 Million Position in Abivax SA Sponsored ADR $ABVX

Key Points

• Affinity Asset Advisors LLC has acquired a new stake in Abivax SA, purchasing 200,000 shares valued at approximately $1.25 million, representing about 0.32% ownership in the company.
• Several institutional investors have increased their positions in Abivax, including Bank of America, which grew its stake by 56.1%, underscoring strong interest in the stock among large players.
• Analysts have issued positive ratings on Abivax, with price targets raised significantly by firms such as JMP Securities and Guggenheim, reflecting increased confidence in the company's growth potential.

Affinity Asset Advisors LLC acquired a new stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 200,000 shares of the company's stock, valued at approximately $1,250,000. Affinity Asset Advisors LLC owned 0.32% of Abivax as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Nantahala Capital Management LLC boosted its stake in shares of Abivax by 45.7% during the fourth quarter. Nantahala Capital Management LLC now owns 1,436,047 shares of the company's stock valued at $10,512,000 after purchasing an additional 450,413 shares during the period. Millennium Management LLC raised its holdings in shares of Abivax by 44.2% during the fourth quarter. Millennium Management LLC now owns 931,179 shares of the company's stock valued at $6,816,000 after acquiring an additional 285,542 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of Abivax by 83.5% during the fourth quarter. Citadel Advisors LLC now owns 855,676 shares of the company's stock valued at $6,264,000 after acquiring an additional 389,247 shares in the last quarter. Caligan Partners LP bought a new position in shares of Abivax during the fourth quarter valued at approximately $5,506,000. Finally, Aberdeen Group plc raised its holdings in shares of Abivax by 67.5% during the first quarter. Aberdeen Group plc now owns 710,516 shares of the company's stock valued at $4,441,000 after acquiring an additional 286,335 shares in the last quarter. Hedge funds and other institutional investors own 47.91% of the company's stock.

Abivax Stock Up 2.8%

ABVX traded up $2.21 during trading on Thursday, reaching $81.64. The stock had a trading volume of 947,592 shares, compared to its average volume of 1,126,268. The stock's 50 day moving average is $42.55 and its two-hundred day moving average is $19.05. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.25 and a quick ratio of 1.25. Abivax SA Sponsored ADR has a one year low of $4.77 and a one year high of $81.95.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ABVX shares. Lifesci Capital upped their target price on Abivax from $45.00 to $101.00 and gave the company an "outperform" rating in a report on Wednesday, July 23rd. Piper Sandler upped their target price on Abivax from $70.00 to $112.00 and gave the company an "overweight" rating in a report on Tuesday, July 29th. Guggenheim upped their target price on Abivax from $50.00 to $101.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. JMP Securities upped their target price on Abivax from $33.00 to $95.00 and gave the company a "market outperform" rating in a report on Wednesday, July 23rd. Finally, Leerink Partners set a $74.00 target price on Abivax and gave the company an "outperform" rating in a report on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. According to data from MarketBeat, Abivax presently has a consensus rating of "Buy" and an average target price of $92.33.

Abivax Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.